Oncogenic CMTM6 drives M2a macrophages formation and fuels cervical cancer progression
Bo Yin1, Chun Chen2, Baoyou Huang1,3
1Department of Gynecology, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, China.
Introduction:
CMTM6, a member of the CKLF like MARVEL transmembrane (CMTM) gene family, has emerged as a critical orchestrator of oncogenic processes, yet its specific role in cervical cancer (CC) remains insufficiently characterized. Mounting evidence implicates that CMTM6 in sculpting an immunosuppressive tumor microenvironment (TME).
Methods:
We investigated the expression and functional role of CMTM6 in CC cells using in vitro biological assays and a mouse xenograft model. The impact of CMTM6 on macrophage polarization and its association with tumor progression were systematically evaluated through a series of in vitro and in vivo experiments, focusing on the induction of M2a macrophage polarization and activation of the mTOR signaling pathway.
Results:
Our results demonstrate that exosomes secreted by CC cells encapsulate CMTM6, which is actively internalized by macrophages, inducing M2a polarization and triggering immunosuppressive pathways. Excessive macrophage infiltration in the TME, particularly in the presence of CMTM6, is strongly associated with unfavorable prognosis. Furthermore, exosomal CMTM6 activates the mTOR signaling pathway in tumor-associated macrophages, enhancing CCL2 secretion, which further promotes M2a polarization and accelerates tumor metastasis.
Discussion:
These findings highlight exosomal CMTM6 as a crucial driver of immune suppression in CC, with the CMTM6/CD206/CCL2 axis significantly increasing the risk for CC patients. Our study underscores the potential of exosomal CMTM6 as both a prognostic biomarker and a therapeutic target for CC immunotherapy.
Insights
Exosomal CMTM6 drives immune suppression in cervical cancer by promoting M2a macrophage polarization and activating the mTOR pathway. This CMTM6/CD206/CCL2 axis worsens prognosis and offers a potential therapeutic target for cervical cancer immunotherapy.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- CMTM6 (CKLF like MARVEL transmembrane member 6) is implicated in cancer progression.
- Its role in cervical cancer (CC) and the tumor microenvironment (TME) is not well understood.
- CMTM6 may contribute to an immunosuppressive TME.
Purpose of the Study:
- To investigate the expression and function of CMTM6 in cervical cancer.
- To determine CMTM6's impact on macrophage polarization and the tumor microenvironment.
- To explore CMTM6 as a potential prognostic biomarker and therapeutic target in CC.
Main Methods:
- In vitro assays and mouse xenograft models were used to study CMTM6 in CC cells.
- Macrophage polarization (M2a) and mTOR signaling pathway activation were evaluated.
- Exosome secretion and uptake by macrophages were analyzed.
Main Results:
- CMTM6 is encapsulated in exosomes secreted by CC cells and taken up by macrophages.
- Exosomal CMTM6 induces M2a macrophage polarization and immunosuppressive pathways.
- CMTM6 presence correlates with increased macrophage infiltration and poor prognosis in CC.
- Exosomal CMTM6 activates mTOR signaling in macrophages, increasing CCL2 secretion, promoting M2a polarization and metastasis.
Conclusions:
- Exosomal CMTM6 is a key driver of immune suppression in cervical cancer.
- The CMTM6/CD206/CCL2 axis is linked to increased risk and unfavorable prognosis in CC patients.
- Exosomal CMTM6 shows potential as a prognostic biomarker and therapeutic target for CC immunotherapy.
Related Concept Videos
Induced Pluripotent Stem Cells
Somatic...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
The Tumor Microenvironment
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...


